Elizabeth Anderson Elizabeth3.Anderson@uwe.ac.uk
Senior Lecturer in Haematology
Rapid in-vitro testing for chemotherapy sensitivity in leukaemia patients
Anderson, Elizabeth; Salisbury, Vyv
Authors
Vyv Salisbury
Contributors
T Scheper
Editor
A Belkin
Editor
PM Doran
Editor
I Endo
Editor
MB Gu
Editor
WS Hu
Editor
B Mattiasson
Editor
J Nielsen
Editor
GN Stephanopoulos
Editor
R Ulber
Editor
A-P Zeng
Editor
J-J Zhong
Editor
W Zhou
Editor
S Harald
Editor
Abstract
© Springer-Verlag Berlin Heidelberg 2014. Bioluminescent bacterial biosensors can be used in a rapid in vitro assay to predict sensitivity to commonly used chemotherapy drugs in acute myeloid leukemia (AML). The nucleoside analog cytarabine (ara-C) is the key agent for treating AML; however, up to 30% of patients fail to respond to treatment. Screening of patient blood samples to determine drug response before commencement of treatment is needed. To achieve this aim, a self-bioluminescent reporter strain of Escherichia coli has been constructed and evaluated for use as an ara-C biosensor and an in vitro assay has been designed to predict ara-C response in clinical samples. Transposition mutagenesis was used to create a cytidine deaminase (cdd)-deficient mutant of E. coli MG1655 that responded to ara-C. The strain was transformed with the luxCDABE operon and used as a whole-cell biosensor for development an 8-h assay to determine ara-C uptake and phosphorylation by leukemic cells. Intracellular concentrations of 0.025 lmol/L phosphorylated ara-C were detected by significantly increased light output (P\0.05) from the bacterial biosensor. Results using AML cell lines with known response to ara-C showed close correlation between the 8-h assay and a 3-day cytotoxicity test for ara-C cell killing. In retrospective tests with 24 clinical samples of bone marrow or peripheral blood, the biosensor-based assay predicted leukemic cell response to ara-C within 8 h. The biosensor-based assay may offer a predictor for evaluating the sensitivity of leukemic cells to ara-C before patients undergo chemotherapy and allow customized treatment of drug-sensitive patients with reduced ara-C dose levels. The 8-h assay monitors intracellular ara-CTP (cytosine arabinoside triphosphate) levels and, if fully validated, may be suitable for use in clinical settings.
Journal Article Type | Article |
---|---|
Publication Date | Jan 1, 2014 |
Journal | Advances in Biochemical Engineering/Biotechnology |
Print ISSN | 0724-6145 |
Publisher | Springer Verlag |
Peer Reviewed | Not Peer Reviewed |
Volume | 145 |
Pages | 189-214 |
Series Title | Advances in Biochemical Engineering/Biotechnology |
Book Title | Bioluminescence: Fundamentals and Applications in Biotechnology - Volume 2 |
ISBN | 0724-6145 |
DOI | https://doi.org/10.1007/978-3-662-43619-6_6 |
Keywords | in-vitro testing, chemotherapy, leukaemia |
Public URL | https://uwe-repository.worktribe.com/output/822778 |
Publisher URL | http://dx.doi.org/10.1007/978-3-662-43619-6_6 |
Related Public URLs | http://link.springer.com/book/10.1007/978-3-662-43619-6 |
You might also like
Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease
(2019)
Presentation / Conference Contribution
Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML).
(2019)
Presentation / Conference Contribution
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search